ArticleExpert review of clinical pharmacology2011
Targeting the off-targets: a computational bioinformatics approach to understanding the polypharmacology of nelfinavir.
Article in Expert review of clinical pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors.International journal of molecular sciences · 2021Article
- Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the identification of new pharmacological effects of already established or abandoned drugs has become a valuable tool for drug repositioning purposes. The HIV drug nelfinavir belongs to those drugs for which empirical data indicate additional pharmacological applications for various diseases, including cancer. To identify and confirm binding partners of nelfinavir other than HIV-1 protease, Xie et al. performed a systematic computational analysis to identify possible structural similarities between the nelfinavir-binding pocket of HIV-1 protease and 5985 protein database entries. Of 126 possible binding partners to nelfinavir, a remarkably high percentage of protein kinases were identified. Further in-depth computational ligand-binding studies indicated the EGF receptor and cytosolic protein kinase B as the most likely off-targets of nelfinavir. Astonishingly, these in silico data are in accordance with previous data obtained by experimental in vitro analysis, indicating a high predictive value of the computer-based approach developed and applied by Xie et al. The computational approach and the authors' results, with respect to their integration in systems biology, are presented and discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.